Research
-
SS-31 News: October 2026 Update
Forzinity's follow-up trial is underway. Fresh mouse and cell studies add research questions, while the label remains limited to Barth syndrome.
-
What Is Bioequivalence? What Generics Must Match
Bioequivalence compares how two medicines reach the body. The 80–125% rule measures study uncertainty, and compounded drugs follow a different route.
-
GHK-Cu News: October 2026 Update
New skin studies add useful detail about GHK-Cu, while human injection benefits remain unsettled. FDA's ingredient review is still pending.
-
Open Enrollment GLP-1 Coverage: 2027 Checklist
Coverage depends on the exact plan, product, and reason for prescribing. This fall's checklist covers dates, approval rules, refill costs, and Medicare's separate Bridge program.
-
Phases of Clinical Trials: What 1, 2, 3 and 4 Mean
Phase 1 checks early safety. Phases 2 and 3 test treatment effects, and phase 4 studies medicines after they reach the market.
-
Semax News Update: October 2026
FDA’s advisory panel supported listing Semax for compounding in July. The published list and the limits of the human studies still matter.
-
CJC-1295 FDA Status: Nominations, Review and Votes
CJC-1295 is not FDA-approved; a compounded prescription is different from an FDA-approved product. Here is what its nominations and votes mean today.
-
What Is an Estimand? Why Trials Report Two Numbers
Two weight-loss numbers from one study can both be right. The difference is often whether the calculation includes treatment stops or assumes continued treatment.
-
TB-500 News Update: October 2026
A new rat study adds tendon data, while the human evidence gap remains. July's FDA review and September's sports list answer different questions.
-
When Did the Tirzepatide Shortage End? The Dates
The FDA took tirzepatide off its shortage list on October 2, 2024. A lawsuit, a second decision and two grace periods followed. Here is the timeline, read from the FDA's own documents, and what it means for a prescription today.
-
California GLP-1 Law: No Immediate Discount
SB 1089 gives California a path to negotiate lower GLP-1 costs. It does not fund a launch, set a patient price or restore Medi-Cal weight-loss coverage.
-
Why Do People Stop Taking GLP-1? Cost Matters
A new semaglutide study links higher patient costs with poorer adherence. The recurring bill deserves a conversation before the first shipment.
-
GLP-1 for Overweight BMI 25: A Case for Trials
A September study found raised heart risk in many adults with BMI 25–26.9. It makes a case for treatment trials, without changing who qualifies today.
-
GLP-1 Nutritional Deficiencies—Children Need Care
A September study found nutrient-deficiency or related-complication diagnoses in about 1 in 6 young GLP-1 patients within a year. The finding highlights early nutrition care, without proving the medicines caused those problems.
-
GLP-1 Without Diabetes or Obesity: Use Is Rising
A September study found more than 1.1 million GLP-1 recipients without documented eligibility. It raises questions about screening and evidence, without judging every prescription.
-
Ozempic Vision Loss Lawsuit: What the Cases Mean
The federal vision-loss cases are pending, and current eye-safety guidance calls for individual treatment decisions. Sudden vision loss needs urgent care.
-
Ribupatide Trials Full; Results Expected in 2028
Kailera has finished recruiting for three global ribupatide trials. Results are expected in mid-2028; the drug remains experimental today.
-
Semaglutide Pancreatic Cancer Study: No Increase
New Nordic findings are reassuring for adults with type 2 diabetes. Short follow-up and excluded medical histories leave important questions open.
-
Survodutide Results: Weight Loss and 18% Dropout
The new diabetes trial reported up to 13.1% average weight loss assuming continued treatment, and 9.8% when counting treatment stops. Stomach and bowel side effects led 18% to stop.
-
What Is a Drug Half-Life? A Plain-English Guide
Half-life is how long it takes the level of a medicine in your blood to fall by half. It explains weekly shots, peptides that clear in minutes, and why a new dose takes weeks to settle.
Page 4 of 8 · 160 articles